Last reviewed · How we verify
NCT05680077
KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
trial testing KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method) in Esophageal Neoplasms in 1,116 participants. Completed in 31 October 2023.
30 August 2023
Quick facts
| Lead sponsor | Wuhan Ammunition Life-tech Co., Ltd |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 1,116 |
| Start date | 28 October 2022 |
| Primary completion | 30 August 2023 |
| Estimated completion | 31 October 2023 |
| Sites | 1 location across China |
Drugs / interventions tested
- KCNA3 and OTOP2 Gene Methylation Combined Detection Kit (Fluorescent PCR Method)
Conditions studied
- Esophageal Neoplasms — all drugs for Esophageal Neoplasms →
Sponsor
Wuhan Ammunition Life-tech Co., Ltd — full company profile →
Who can join
40 and older, any sex, with Esophageal Neoplasms. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this observational study is to test the clinical efficacy of "KCNA3 and OTOP2 gene methylation combined detection kit (fluorescence PCR method)"in esophageal cancer and high-grade esophageal neoplasia auxiliary diagnosis.The main questions it aims to answer are: 1. How consistent are the test results of the kit with the clinical reference diagnostic criteria? 2. Sanger sequencing can visually show whether each sample contains methylation sites, so in this clinical trial, the kit results were compared with Sanger sequencing results to analyze the reagent's accuracy in detecting KCNA3 and OTOP2 gene methylation. Each participant is required to provide no less than 10 ml of blood to complete the kit test.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Genome-wide methylation profiling identified methylated KCNA3 and OTOP2 as promising diagnostic markers for esophageal squamous cell carcinoma.
Bian Y, Gao Y, Lu C, Tian B, et al · · 2024 · cited 15× · PMID 37650127 · DOI 10.1097/cm9.0000000000002832
Verify or expand the search:
- PubMed search for NCT05680077
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Esophageal Neoplasms
Currently open trials in the same condition.
- NCT07482566 — Proximal Versus Total Gastrectomy for Locally Advanced Siewert Type II-III Gastroesophageal Junction Cancer · NA · recruiting
- NCT07272382 — Omega-3 Fatty Acids With PD-1 Inhibitors in Advanced Esophageal Cancer · NA · recruiting
- NCT06469944 — Substudy 06C: A Study of Investigational Agents With Pembrolizumab (MK-3475) and Chemotherapy in Participants With First · Phase 1, PHASE2 · recruiting
- NCT07035587 — Diagnosis of Multiple Cancer and Monitoring of Minimal Residual Tumors After Treatment Using Blood and High-Sensitivity · recruiting
- NCT06445972 — Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06) · Phase 1, PHASE2 · recruiting
Other Wuhan Ammunition Life-tech Co., Ltd trials
Trials by the same sponsor.
- NCT07466602 — cfDNA Methylation for Liver Cancer Recurrence Detection · recruiting
- NCT06564363 — The Efficacy of the IUrisure for Detection of Recurrent Urothelial Carcinoma · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05680077 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Wuhan Ammunition Life-tech Co., Ltd
- Last refreshed: 13 February 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05680077.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing